Navigation Links
Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer -

LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that positive Phase III clinical data published in the July 1 issue of the Journal of Clinical Oncology suggests that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology. Data from previous studies published by the Company in Clinical Cancer Research 2002 and Annals of Oncology 2006 showing that ERCC-1 was associated with tumor sensitivity to cisplatin formed the basis for the present study. This is the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.

The Phase III multicenter, randomized study was designed to determine the overall response rate (complete plus partial responses) of patients with stage IIIb or IV NSCLC to cisplatin-based therapy by determining levels of the biomarker ERCC-1 mRNA in their paraffin-embedded tissue biopsy before administering treatment. Patients were prospectively assigned treatment to a cisplatin or non-cisplatin-based chemotherapy depending on whether the ERCC-1 gene expression in their tumor sample was above or below a specific threshold. Patients were assigned to one of two arms in this trial. The control arm consisted of all patients receiving cisplatin-based therapy. Patients in the "genotypic" arm were separated by levels of ERCC-1. Cisplatin-based therapy (docetaxel/cisplatin) was assigned to patients with low
'"/>




Page: 1 2 3 4

Related medicine technology :

1. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
10. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
11. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
Post Your Comments:
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... BEDFORD, Mass. , May 23, 2013 /PRNewswire/ ... HOLX ), a leading developer, manufacturer and ... surgical products, with an emphasis on serving the ... first large-scale observational study in a U.S. clinical ... mammography technology (breast tomosynthesis) with conventional 2D mammography ...
(Date:5/23/2013)...  Ameritox, the nation,s leader in pain medication ... to become part of its Urine Drug Monitoring ... and improve the clinical outcomes for injured workers. ... manager in the workers, compensation industry, has used ... management strategy for several years. By establishing a ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... Amgen (Nasdaq: AMGN ) will participate in ... the St. Regis New York in New York City, beginning ... president of Global Development, for Amgen, will present at the ... the Internet and can be accessed from Amgen,s website, ...
... Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: ... it has filed a Supplemental Biologics License Application (sBLA) with ... Intradermal (Influenza Virus Vaccine).  The file has been accepted ... the first half of 2011. "Upon FDA ...
Cached Medicine Technology:FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection 2FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection 3FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection 4
(Date:5/23/2013)... (PRWEB) May 23, 2013 Voyance, ... and perception management tools, and ASCA, the industry’s ... the new ASCA Benchmarking Program. Voyance ... technology and national benchmarking experience to support ASCA’s ... comprehensive, state-of-the-art benchmarking tool. , “Voyance is both ...
(Date:5/23/2013)... Today, Zane Benefits, Inc. published a ... Benefits, which provides comprehensive and flexible alternatives to traditional ... defined contribution plans and health reimbursement arrangements ... from employees is “does my employer have to provide ... The health care reform law, called the Affordable Care ...
(Date:5/23/2013)... May 23, 2013 Da Vinci surgical ... a trial in Washington State May 23, according to ... in surgical robot lawsuits , expresses disappointment in ... Vinci lawsuits to not read a single verdict as ... (Estate of Fred E. Taylor v. Intuitive Surgical Inc.; ...
(Date:5/23/2013)... News) -- A modified version of the polio ... preliminary research suggests. Scientists at Duke Cancer ... PVSRIPO, uses an engineered form of the virus ... cancer cells. The therapy shows promise in the ... brain tumor, they said. "These early results ...
(Date:5/23/2013)... it when a woman harried by hot flashes says ... study published online in Menopause , the journal ... with objective tests that what these women say about ... studies showed that hot flashes were related to memory ... though there was a relationship between hot flashes and ...
Breaking Medicine News(10 mins):Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2
... US researchers report that antibodies extracted from the blood of ... dreaded H5N1 bird flu virus. ,Scientists have ... a new therapy for the hard-to-treat H5N1 flu strain. ... to stockpile these antibodies, the immune system's search-and-destroy force, as ...
... revealed that bricks made from fly-ash particles captured as waste ... ,Rather than leach minute amounts of mercury as ... minute amounts of the toxic metal out of ambient air. ... Science Foundation (NSF) awardee and the president of Freight Pipeline ...
... Tuesday slammed the tobacco industry for spreading untruths about smoking ... number of smoking bans around the world. ... misinformed the public about the health risks and dangers of ... bans." ,"We all know that smoking kills," Shigeru ...
... whose blood shows signs of inflammation are more likely ... signs of inflammation, according to a study published ... scientific journal of the American Academy of Neurology. ... Framingham Heart Study, involved 691 healthy people with an ...
... resonance imaging (MRI), radiologists can better predict the likelihood ... spinal cord injuries (SCI), according to a study ... ,"Our study demonstrates that the possibility and ... within 48 hours after injury by rigorous assessment of ...
... senior doctor with the Apollo Hospital here allegedly committed suicide ... dispute. ,Umesh Sharma, president of the orthopaedics department, ... in Apollo Hospital in Sarita Vihar, south Delhi. ... dispute, came to the hospital at around 6.00 a.m. to ...
Cached Medicine News:Health News:Blood from Bird Flu Survivors Provides Breakthrough in Treatment of H5N1 2Health News:Fly Ash Bricks are Absolutely Safer Than Actually Predicted 2Health News:WHO Condemns Tobacco Industry for Misleading Public 2Health News:Recovery from Spinal Cord Injury can Be Predicted Using MRI 2
... delivers the performance and reliability ... management systems. As the industry ... set the benchmark. When it ... performance and technological longevity, Heartlab's ...
... first digital solution designed specifically for cardiologists ... outside cardiology. From the server core to ... combined expertise in both cine film and ... work the way they want, wherever they ...
Precision near-field imaging combined with the best handling IVUS catheter....
... Medison SonoAce 9900 is ... based ultrasound system, with ... is DICOM compatible, designed ... general imaging, obstetrics, gynecology, ...
Medicine Products: